Conference Description:

Recognised with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms.

The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects and enabling efficient tissue-specific delivery to help you progress your program into and through the clinic.

Across three days of content, carefully co-designed with industry thought leaders, this streamlined one-track summit will unite key players in the CRISPR space, from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to market for your CRISPR gene editing program.

Tickets: https://go.evvnt.com/1278515-3?pid=154
Time: 08:30 - 17:00

Prices:
FULL PACKAGE: Conference + Workshop Day - Physical - Drug Developer: USD 4097.00,
Conference Only - Physical - Drug Developer: USD 2899.00,
FULL PACKAGE: Conference + Workshop Day - Physical - Academic: USD 3497.00,
Conference Only - Physical - Academic: USD 2499.00,
FULL PACKAGE: Conference + Workshop Day - Physical - Solution Provider: USD 4897.00,
Conference Only - Physical - Solution Provider: USD 3499.00

Speakers: Aditya Raguram, PhD Student David Liu Lab, Harvard University, Alexandra Crawley, Co-Founder and Senior Scientist, LifeEDIT, Amy Simon, Chief Medical Officer, Beam Therapeutics, Benjamin Oakes, Co-Founder and Chief Executive Officer, Scribe Therapeutics, Carlo Zambonelli, Senior Director - Analytical Sciences, Beam Therapeutics, Danilo Maddalo, Group Leader - Translational Oncology, Genentech, David Guay, Vice President Innovation and Technology, Feldan Therapeutics, Eric B. Kmiec, Executive Director and Chief Scientific Officer, ChristianaCare Gene Editing Institute, Guillaume Pavlovic, Head of Genetic Engineering and Model Validation Department, Institut Clinique De La Souris, Howard Wu, Founder and Chief Scientific Officer, Full Circles Therapeutics, Inge Yung-Chih Cheng, Principal Scientist, Pfizer, Ira Gotliv, Vice President - Preclinical Research, Emendo Biotherapeutics, Jane Grogan, Chief Scientific Officer, Graphite Bio, Jeremy Duffield, Chief Scientific Officer, Prime Medicine, Joey Riepsaame, Head of Genome Engineering, University of Oxford, John Murphy, Chief Scientific Officer, Arbor Biotechnologies, Jonathan Yen, Director of Therapeutic Genome Engineering, St. Jude Children's Research Hospital, Kiran Musunuru, Professor of Medicine Director, Perelman School of Medicine, University of Pennsylvania, Liron Walsh, Head of Development; In Vivo Programs, Intellia Therapeutics, Paul Donohue, Senior Scientist - Platform Discovery Group Lead, Caribou Biosciences, Rafi Emmanuel, Senior Vice President - Research and Development, Emendo Biotherapeutics, Rajarshi Choudhury ,Associate Director - Genomic Sciences, GSK, Rammohan Devulapally, Principal Scientist - Drug Delivery Chemistry and Nanoparticle Formulation Development, GenEdit, Roberto Nitsch, Associate Director, AstraZeneca, Samuel Du MD-PhD, Student, Krzysztof Palczewski Lab, University of California Irvine, Weston Miller, Vice President - Clinical Development, Graphite Bio